C5G Stock Chart & Stats
€1.31
-€0.02(-1.20%)
At close: 4:00 PM EDT
€1.31
-€0.02(-1.20%)
Day’s Range― - ―
52-Week Range€1.16 - €3.83
Previous CloseN/A
Volume0.00
Average Volume (3M)215.00
Market Cap
€41.75M
Enterprise Value€576.03
Total Cash (Recent Filing)€276.90M
Total Debt (Recent Filing)€9.90M
Price to Earnings (P/E)―
Beta0.60
Next Earnings
Oct 22, 2026EPS Estimate
-0.19Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-8.81
Shares Outstanding35,127,056
10 Day Avg. Volume527
30 Day Avg. Volume215
Financial Highlights & Ratios
PEG Ratio0.22
Price to Book (P/B)2.12
Price to Sales (P/S)40.09
P/FCF Ratio6.02
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.82
Revenue Forecast (FY)€2.36M
Bulls Say, Bears Say
Bulls Say
Long-lived IP And PipelineLong patent runways can protect future products from direct competition and support partnering or licensing value. OX640, GLP-1 and other AmorphOX programs provide multiple potential growth avenues beyond Orexo’s legacy products.
Pipeline And Funding ProgressPositive preclinical progress and external BARDA financing reduce Orexo’s direct funding burden for OX390 while advancing a potential new product. Continued development progress can diversify the portfolio and improve strategic partnering prospects.
Improved Leverage And Cost BaseLower leverage provides more financial flexibility than in prior periods, while the normalized cost base indicates savings after one-off expenses and transition costs. Together, these factors could improve resilience if product revenue and partnerships recover.
Bears Say
Severe Profitability And Revenue PressureThe core business is currently not covering its cost base, and the sharp revenue decline weakens operating leverage. Persistent losses could limit investment capacity and make Orexo increasingly dependent on successful launches, licensing or external financing.
Cash Burn And Uncertain DurabilityRecent cash generation has not been sustained: a large quarterly outflow materially reduced available liquidity despite reported cash reserves. Continued development spending, legal costs and low revenue could accelerate funding needs before new products contribute.
DOJ And Financing UncertaintyAn unresolved investigation creates potentially material legal liabilities and ongoing advisory costs while complicating capital planning. Until the outcome is known, financing flexibility may remain limited and partners or investors may require greater risk compensation.
Orexo AB News
C5G FAQ
What was Orexo AB’s price range in the past 12 months?
Orexo AB lowest stock price was €1.16 and its highest was €3.83 in the past 12 months.
What is Orexo AB’s market cap?
Orexo AB’s market cap is €41.75M.
When is Orexo AB’s upcoming earnings report date?
Orexo AB’s upcoming earnings report date is Oct 22, 2026 which is in 55 days.
How were Orexo AB’s earnings last quarter?
Orexo AB released its earnings results on Jul 16, 2026. The company reported -€0.199 earnings per share for the quarter, missing the consensus estimate of -€0.145 by -€0.054.
Is Orexo AB overvalued?
According to Wall Street analysts Orexo AB’s price is currently Overvalued.
Does Orexo AB pay dividends?
Orexo AB does not currently pay dividends.
What is Orexo AB’s EPS estimate?
Orexo AB’s EPS estimate is -0.19.
How many shares outstanding does Orexo AB have?
Orexo AB has 35,127,056 shares outstanding.
What happened to Orexo AB’s price movement after its last earnings report?
Orexo AB reported an EPS of -€0.199 in its last earnings report, missing expectations of -€0.145. Following the earnings report the stock price went down -4.133%.
Which hedge fund is a major shareholder of Orexo AB?
Currently, no hedge funds are holding shares in DE:C5G
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Orexo AB
Orexo AB (publ), a specialty pharmaceutical company, develops and commercializes pharmaceuticals and digital therapies in the United States, European Union, the United Kingdom, and internationally. Its products include Zubsolv tablets for the treatment of opioid use disorder; Abstral for the treatment of breakthrough pain in cancer patients; and Edluar for the treatment of insomnia. The company is developing OX124 for opioid overdose; OX125 for rescue medication and opioid overdose; OX640 to treat anaphylaxis with powder-based epinephrine; and OX-MPI for the treatment of endometriosis. Its digital therapies include deprexis for the treatment of depression; vorvida for alcohol management; and modia for opioid use disorder. The company has a collaboration agreement with Abera Bioscience AB to develop nasal powder vaccines based on the AmorphOX technology. Orexo AB (publ) was founded in 1994 and is headquartered in Uppsala, Sweden.
C5G Company Deck
C5G Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call presents a mixed picture: strong scientific and programmatic progress (positive in vivo data for OX390, Izipry filing on track, OX640 progression, BARDA funding, and business development momentum) and valuable strategic assets (long IP life, AmorphOX platform interest). However, short-term financials are challenged by material one-off costs (GAIA settlement), ongoing DOJ uncertainty, substantial quarterly cash burn and low revenues. Management has clear plans to reduce run-rate OpEx and pursue partnerships and financing, but timing and DOJ resolution are key near-term risks.View all DE:C5G earnings summariesTechnical Analysis
Swedish Orphan Biovitrum AB
―
Camurus AB
―
AlzeCure Pharma AB
―
IRLAB Therapeutics AB Class A
―
Xspray Pharma AB
―